Last edition
News about "Phase II study"
Citius Oncology reports positive Phase I data showing encouraging safety and response rates for LYMPHIR combined with Keytruda in recurrent gynecologic cancers, supporting further Phase II evaluation.
Phase II Study | 11/03/2026 | By News Bureau | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members